Unow™ Drug Residue Test Device to Revolutionize Safety Protocols in Canada

Taizhou Kaimi Biotech and Scenesafe have partnered to introduce the Unow™ Drug Residue Test Device in Canada, offering a groundbreaking solution for detecting hazardous substance residues across various professional environments. The portable device enables users to identify trace amounts of illicit substances, including opioids, fentanyl, and methamphetamine, with remarkable speed and precision.

The innovative testing technology addresses critical safety concerns by providing rapid, on-site detection capabilities for multiple sectors. Law enforcement agencies can conduct immediate investigations, healthcare facilities can ensure sterile environments, remediation teams can validate decontamination efforts, and property managers can safeguard residential and commercial spaces.

This strategic partnership combines Taizhou Kaimi Biotech's technological expertise with Scenesafe's comprehensive understanding of Canadian safety protocols. By delivering laboratory-grade results within minutes, the Unow™ device represents a significant advancement in portable diagnostic technologies.

According to Otis Zhao, President of Taizhou Kaimi Biotech, the device aims to protect communities by providing an accessible tool for identifying potentially dangerous drug residues. Hang Ai of Scenesafe emphasized the device's potential to mitigate risks for first responders, families, and businesses by offering immediate environmental safety verification.

The Unow™ Drug Residue Test Device is scheduled for Canadian market release in the second quarter of 2025, signaling a potential transformation in how organizations approach substance contamination detection and prevention.